Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)
Authors: Aart-Jan van der Lely, Karin Foeken, Roos C. van der Mast, Steven W. J. Lamberts
Journal: Annals of Internal Medicine (1991)

Brief Reports15 January 1991Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)Aart-Jan van der Lely, MD, Karin Foeken, MD, Roos C. van der Mast, MD, Steven W. J. Lamberts, MDAart-Jan van der Lely, MD, Karin Foeken, MD, Roos C. van der Mast, MD, Steven W. J. Lamberts, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-2-143 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe progesterone-receptor antagonist, RU 486 (mifepristone), is also, at higher concentrations, an effective antagonist of glucocorticoid action in vitro and in vivo (1-3). In normal humans, RU 486 blocks glucocorticoid negative feedback at the hypothalamic-pituitary level, inducing a compensatory increase in plasma adrenocorticotropin (ACTH) and cortisol levels (4, 5). In previous studies, patients with the Cushing syndrome caused by ectopic ACTH secretion or by adrenocortical carcinomas who received therapy with RU 486 (5 to 22 mg/kg body weight per day) showed clinical improvement, and no compensatory increases in plasma ACTH or cortisol levels were noted, probably because of ongoing hypothalamic...References1. Philibert D, Deraedt R, and Teutsch G. RU 486: a potent antiglucocorticoid in vivo [Abstract]. International Congress of Pharmacology, Tokyo, Japan; 1981:1463. Google Scholar2. Proux-Ferland L, Cote J, Philibert D, and Deraedt R. Potent antiglucocorticoid activity of RU 38486 on ACTH secretion in vitro and in vivo in the rat [Abstract]. J Steroid Biochem. 1982;17:xvii. Google Scholar3. Lamberts S, Bons E, and Uitterlinden P. Studies on the glucocorticoid receptor blocking action of RU 38486 in cultured ACTH-secreting human pituitary tumor cells and normal rat pituitary cells. Acta Endocrinol (Copenh). 1985;109:64-9. CrossrefMedlineGoogle Scholar4. Bertagna X, Bertagna C, Luton J, Husson J, and Girard F. The new steroid analogue RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab. 1984;59:25-31. CrossrefMedlineGoogle Scholar5. Gaillard R, Poffet D, Diondel A, and Saurat J. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab. 1985;61:1009-14. CrossrefMedlineGoogle Scholar6. Bertagna X, Bertagna C, Laudat M, Husson J, Girard F, and Luton Z. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63:639-42. CrossrefMedlineGoogle Scholar7. Nieman L, Chrousos G, and Nisula B. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61:536-40. CrossrefMedlineGoogle Scholar8. Nieman L, Udelsman R, Loriaux D, and Chrousos C. Antiglucocorticoids: basic and clinical studies. In: D'Agata R, Chrousos GP, eds. Recent Advances in Adrenal Regulation and Function. New York: Raven Press; 1987:235-58. Google Scholar9. Haskett R. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry. 1985;142:911-6. CrossrefMedlineGoogle Scholar10. Laue L, Callucci W, Loriaux D, Udelsman R, and Chrousos G. The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. J Clin Endocrinol Metab. 1988;67:602-6. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Aart-Jan van der Lely, MD; Karin Foeken, MD; Roos C. van der Mast, MD; Steven W. J. Lamberts, MDFrom Erasmus University, Rotterdam, The Netherlands. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGlucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterationsMifepristone's effects on depression- and anxiety-like behavior in rodentsEndokrine StörungenSex differences in the hypothalamic–pituitary–adrenal axis: An obstacle to antidepressant drug development?Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional PerspectiveManage psychiatric symptoms in Cushing's syndrome by controlling cortisol levels and usual psychiatric therapyMifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic DepressionPsychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and ManagementUpdate on medical treatment for Cushing's diseaseA Mixed Glucocorticoid/Mineralocorticoid Selective Modulator With Dominant Antagonism in the Male Rat BrainAnna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamic–pituitary–adrenal (HPA) axis in the pathogenesis of psychotic major depressionTreatment of Cushing's disease: a mechanistic updateNext Generation Medical Therapy for Cushing's Syndrome—Can We Measure a Benefit?Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric AspectsAll-trans retinoic acid-induced hypothalamus–pituitary–adrenal hyperactivity involves glucocorticoid receptor dysregulationStress and neurodevelopmental processes in the emergence of psychosisMifepristone: is there a place in the treatment of Cushing's disease?Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behaviorA New Therapeutic Approach in the Medical Treatment of Cushing'S SYNDROME: GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONEA Role for Selective Serotonin Reuptake Inhibitors in the Management of Residual Cognitive Dysfunction in Pediatric Cushing's DiseaseThe use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndromeMetyrapone in treatment-resistant depressionMifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's SyndromeAntidepressivaCentral Dopaminergic System and Its Implications in Stress-Mediated Neurological Disorders and Gastric Ulcers: Short ReviewCorticosteroid Receptor Involvement in the Stress ResponseMaternal dexamethasone and EEG hyperactivity in preterm fetal sheepCushing's diseaseCorticosteroid receptor signalling modes and stress adaptation in the brainFrom vasotocin to stress and cognitionStress Hormone Regulation: Biological Role and Translation into TherapyMerits and pitfalls of mifepristone in Cushing's syndromeGlucocorticoid Receptor Blockade Normalizes Hippocampal Alterations and Cognitive Impairment in Streptozotocin-Induced Type 1 Diabetes MicePharmacotherapy for Hormone Excess in Adrenocortical CarcinomaInnovative Approaches for the Treatment of Depression: Targeting the HPA AxisSelective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systemsGlucocorticoid antagonists in neuropsychotic disordersA case of hypocortisolemic clinical Cushing's syndromeTreatment of severe psychosis due to ectopic Cushing's syndromeTherapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression?The use of mifepristone in the treatment of neuropsychiatric disordersPsychotic Major DepressionRole of glucocorticoids in dopamine-related neuropsychiatric disordersStress and the brain: from adaptation to diseaseEffect of phenytoin on mood and declarative memory during prescription corticosteroid therapyThe Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and diseaseCorticosteroid receptors and HPA-axis regulationGlucocorticoid antagonists and depressionShort ReviewGlucocorticoid Receptor Antagonists: New Tools to Investigate Disorders Characterized by Cortisol HypersecretionCortisol, depression and reduced cortico-cortical cross-talk in Cushing's syndromeHormones and the Stressed BrainEffect of Chronic Administration of Selective Glucocorticoid Receptor Antagonists on the Rat Hypothalamic–Pituitary–Adrenocortical AxisChallenges in the treatment of depression with psychotic featuresDrug-Related Adrenal InsufficiencyBlockade of glucocorticoid receptors with ORG 34116 does not normalize stress-induced symptoms in male tree shrewsNovel Strategies in the Treatment of Psychotic Major DepressionAn open label trial of C-1073 (mifepristone) for psychotic major depression*New directions in the development of antidepressants: the interface of neurobiology and psychiatryCorticosteroids, immune suppression, and psychosisCould Stress Cause Psychosis in Individuals Vulnerable to Schizophrenia?Rapid Reversal of Psychotic Depression Using MifepristoneHypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinomaPsychiatric Disorders Associated with Cushing??s SyndromeStress Hormone-Related Psychopathology: Pathophysiological and Treatment ImplicationsTratamento medicamentoso dos tumores hipofisários. parte II: adenomas secretores de ACTH, TSH e adenomas clinicamente não-funcionantesTreatment of Depression With Antiglucocorticoid DrugsMechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450Differential inducibility of specific mRNA corresponding to five CYP3A isoforms in female rat liver by RU486 and food deprivationRU486 (MIFEPRISTONE): Mechanisms of Action and Clinical UsesIdentification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomesMifepristone: Treatment of Cushing's SyndromeClinical Uses of Mifepristone (MFP)Blockade of the Glucocorticoid Receptor with RU 486: Effects In Vitro and In Vivo on Human Adipose Tissue Lipoprotein Lipase ActivityPituitary adenomas, some diagnostic and therapeutical aspectsCushing's Syndrome and HypertensionThe Pathophysiologic Significance of Hyperadrenocorticism: Antiglucocorticoid StrategiesLong-term treatment with RU486 and glucocorticoid receptor resistance Theoretical and therapeutic implicationsSleep and Quality of Life in Endocrine Diseases 15 January 1991Volume 114, Issue 2Page: 143-144KeywordsAdrenocorticotropic hormoneAttentionBlood plasmaBody weightCortisolHospital medicine ePublished: 1 December 2008 Issue Published: 15 January 1991 PDF downloadLoading ...